Comparative Pharmacology
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus NASACORT HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus NASACORT HFA.
FLUTICASONE PROPIONATE vs NASACORT HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; binds to cytosolic glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins, leukotrienes) and suppression of immune cell activity.
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal inflammation.
Inhalation: 88-440 mcg twice daily for asthma (DPI: 100-500 mcg twice daily; HFA: 44-220 mcg twice daily). Intranasal: 2 sprays (50 mcg/spray) per nostril once daily (total 200 mcg/day). Topical: Apply thin layer to affected area 1-2 times daily.
55 mcg (1 spray) per nostril once daily; may increase to 110 mcg (2 sprays) per nostril once daily if needed. Maximum 440 mcg/day total.
None Documented
None Documented
Clinical Note
moderateFluticasone propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin."
Clinical Note
moderateFluticasone propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin."
Clinical Note
moderateFluticasone propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 7.8 hours after intravenous administration; extends to 10-14 hours following intranasal or inhaled routes due to slow absorption from the lung/nasal mucosa.
Terminal elimination half-life is approximately 3.5 hours following intranasal administration, reflecting slow systemic absorption and prolonged local retention.
Primarily hepatic metabolism via CYP3A4 to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal elimination accounts for >90% of metabolites.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites and parent drug)
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
Fluticasone propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trovafloxacin."